Xeris Biopharma Holdings, Inc. (XERS) FY2025 10-K Annual Report
Xeris Biopharma Holdings, Inc. (XERS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 2, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Xeris Biopharma Holdings, Inc. FY2025 10-K Analysis
Business Overview
- • Commercial-stage biopharma focused on therapies for chronic endocrine and neurological diseases in the U.S., with three commercial products: Recorlev, Gvoke, Keveyis
- • Phase 3-ready XP-8121: once-weekly subcutaneous levothyroxine injection leveraging proprietary XeriSol tech, planned Phase 3 start in 2026
- • Strategic emphasis on pipeline leveraging proprietary non-aqueous formulation tech (XeriSol/XeriJect) for improved drug delivery and new licensing partnerships
- • Patent protection for key products: Recorlev (orphan drug exclusivity through 2028, patents to 2040), Gvoke patents to 2036; Keveyis lost orphan exclusivity in 2022, facing generic competition
- • Noteworthy: Positive Phase 2 data for XP-8121 with 72% patient preference for weekly injection; FDA agreed on single non-inferiority Phase 3 trial design
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in the provided MD&A section
- • Financing cash inflow $11.4M in 2025 vs $36.2M in 2024; driven by $20.7M stock awards and $10.9M stock repurchases
- • Investing cash outflow $696K in 2025 vs inflow $4.9M in 2024 due to fewer short-term investment purchases
- • No segment performance data or forward-looking guidance included in the excerpt
Risk Factors
- • Risk of SBA PPP Loan audit/enforcement under CARES Act until May 2026, potentially diverting management resources and incurring costs
- • Geopolitical and macroeconomic risks impairing capital access due to inflation, interest rates, bank failures, and financial market volatility
- • Supply chain and inventory risks with potential product returns exceeding reserves, reliant on third-party data accuracy for return estimates
- • Competitive threats to Recorlev from Corcept Therapeutics' Korlym, Recordati's Signifor LAR and Isturisa, and potential ketoconazole approval in US
- • Financial risk from $200M term loans and $33.6M 8.00% Convertible Notes secured by company assets, with restrictive covenants limiting operations
Xeris Biopharma Holdings, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$292M
▲ +43.7% YoY
Net Income
$554,000
▲ +101.0% YoY
Operating Margin
8.5%
▲ +2510bp YoY
Net Margin
0.2%
▲ +2719bp YoY
ROE
4.0%
▼ -18112bp YoY
Total Assets
$384M
▲ +18.7% YoY
EPS (Diluted)
$0.00
▲ +100.0% YoY
Operating Cash Flow
$29M
▲ +177.4% YoY
Source: XBRL data from Xeris Biopharma Holdings, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Xeris Biopharma Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.